Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors

被引：37

作者：

Kurukulasuriya, L. Romayne ^{[1
]}

Sowers, James R. ^{[1
,2
]}

机构：

[1] UMC, Dept Internal Med, Div Endocrinol Diabet & Metab, Diabet Ctr D109, Columbia, MO 65212 USA

[2] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA

来源：

CARDIOVASCULAR DIABETOLOGY | 2010年 / 9卷

关键词：

DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; ONGOING METFORMIN THERAPY; GLYCEMIC CONTROL; BLOOD-PRESSURE; EXENATIDE EXENDIN-4; INFLAMMATORY MARKERS; INSULIN SENSITIVITY; JAPANESE PATIENTS; SYNTHETIC ANALOG;

D O I：

10.1186/1475-2840-9-45

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: To summarize data supporting the effects of antidiabetes agents on glucose control and cardiovascular risk factors in patients with type 2 diabetes. Methods: Studies reporting on the effects of antidiabetes agents on glycemic control, body weight, lipid levels, and blood pressure parameters are reviewed and summarized for the purpose of selecting optimal therapeutic regimens for patients with type 2 diabetes. Results: National guidelines recommend the aggressive management of cardiovascular risk factors in patients with type 2 diabetes, including weight loss and achieving lipid and blood pressure treatment goals. All antidiabetes pharmacotherapies lower glucose; however, effects on cardiovascular risk factors vary greatly among agents. While thiazolidinediones, sulfonylureas, and insulin are associated with weight gain, dipeptidyl peptidase-4 inhibitors are considered weight neutral and metformin can be weight neutral or associated with a small weight loss. Glucagon-like peptide-1 receptor agonists and amylinomimetics (e.g. pramlintide) result in weight loss. Additionally, metformin, thiazolidinediones, insulin, and glucagon-like peptide-1 receptor agonists have demonstrated beneficial effects on lipid and blood pressure parameters. Conclusion: Management of the cardiovascular risk factors experienced by patients with type 2 diabetes requires a multidisciplinary approach with implementation of treatment strategies to achieve not only glycemic goals but to improve and/or correct the underlying cardiovascular risk factors.

引用

页数：13

共 50 条

[21] Previous dramatic reduction of HbA1c and retinopathy in Type 2 Diabetes [J].

Larroumet, Alice ;

Rigo, Marine ;

Lecocq, Maxime ;

Delyfer, Marie-Noelle ;

Korobelnik, Jean-Francois ;

Monlun, Marie ;

Foussard, Ninon ;

Poupon, Pauline ;

Blanco, Laurence ;

Mohammedi, Kamel ;

Rigalleau, Vincent .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (07)

[22] Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia [J].

Yamakawa, Tadashi ;

Kaneko, Takeshi ;

Shigematu, Erina ;

Kawaguchi, Junko ;

Kadonosono, Kazuaki ;

Morita, Satoshi ;

Terauchi, Yasuo .

ENDOCRINE JOURNAL, 2011, 58 (03) :185-191

[23] Effect of nurse-led randomised control trials on cardiovascular risk factors and HbA1c in diabetes patients: A meta-analysis [J].

Daly, Barbara ;

Tian, Catherine Jia Lin ;

Scragg, Robert Keith Rhodes .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 131 :187-199

[24] Independent Association of HbA1c and Incident Cardiovascular Disease in People Without Diabetes [J].

Adams, Robert J. ;

Appleton, Sarah L. ;

Hill, Catherine L. ;

Wilson, David H. ;

Taylor, Anne W. ;

Chittleborough, Catherine R. ;

Gill, Tiffany K. ;

Ruffin, Richard E. .

OBESITY, 2009, 17 (03) :559-563

[25] Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study [J].

Gomes, Marilia B. ;

Tang, Fengming ;

Chen, Hungta ;

Cid-Ruzafa, Javier ;

Fenici, Peter ;

Khunti, Kamlesh ;

Rathmann, Wolfgang ;

Shestakova, Marina V. ;

Surmont, Filip ;

Watada, Hirotaka ;

Medina, Jesus ;

Shimomura, Iichiro ;

Saraiva, Gabriela Luporini ;

Cooper, Andrew ;

Nicolucci, Antonio .

FRONTIERS IN ENDOCRINOLOGY, 2022, 13

[26] Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT [J].

Lingvay, Ildiko ;

Deanfield, John ;

Kahn, Steven E. ;

Weeke, Peter E. ;

Toplak, Hermann ;

Scirica, Benjamin M. ;

Ryden, Lars ;

Rathor, Naveen ;

Plutzky, Jorge ;

Morales, Cristobal ;

Lincoff, A. Michael ;

Lehrke, Michael ;

Jeppesen, Ole Kleist ;

Gajos, Grzegorz ;

Colhoun, Helen M. ;

Cariou, Bertrand ;

Ryan, Donna .

DIABETES CARE, 2024, 47 (08) :1360-1369

[27] Going beyond HbA1c to understand the benefits of advanced diabetes therapies [J].

Vigersky, Robert A. .

JOURNAL OF DIABETES, 2019, 11 (01) :23-31

[28] Statins are independently associated with increased HbA1c in type 1 diabetes - The Thousand & 1 Study [J].

Jensen, Magnus Thorsten ;

Andersen, Henrik Ullits ;

Rossing, Peter ;

Jensen, Jan Skov .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 111 :51-57

[29] HbA1c for screening and diagnosis of diabetes mellitus [J].

Higgins, Trefor .

ENDOCRINE, 2013, 43 (02) :266-273

[30] The phenomenon of HbA1c stability and the risk of hypoglycemia in long-standing type 1 diabetes [J].

Wolnik, B. ;

Orlowska-Kunikowska, E. ;

Blaszkowska, M. ;

Graff, B. ;

Wolf, J. ;

Czupryniak, L. ;

Narkiewicz, K. .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 152 :96-102

← 1 2 3 4 5 →